About this trial
Stroke is a leading cause of death and disability worldwide. A major complication of stroke is spasticity, marked by increased muscle tone and impaired movement. It affects majority stroke patients and complicates rehabilitation, affecting the upper limb function of survivors.
While traditional treatments like oral medications and botulinum toxin injections offer some relief, they have notable limitations, causing the need for novel, non-invasive approaches. Extracorporeal shock wave therapy (ESWT), which uses acoustic waves for regeneration and neuromodulation, has shown promise in reducing spasticity with minimal side effects, though its precise mechanisms and ideal protocols need further study. Current evidence supports ESWT's efficacy and safety, often matching established treatments, but gaps remain regarding standardized application and long-term functional outcomes, highlighting the need for more robust research.
Eligibility criteria
Qualifiers
Diagnosed as 1st stroke incidence 6 months back
Both male and female
Age 25 to 65 years
the ability to follow verbal instructions
Disqualifiers
Recurrent stroke.
Severe contractures or deformities of upper extremity.
Chronic pain affecting upper extremity function.
malignant tumor, pacemakers, infection
Trial design
Treatments tested in this trial
- ESWT
- Stretching
- Mobility
- Strengthening
- Functional training